| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Registrational U.S. AURORA Phase 3 clinical trial underway for denifanstat in moderate to severe acne, with topline data anticipated in the second half of 2027 |
| 22 Oct 2026 |
8-K: Regulation FD Disclosure
Targeting Metabolic Dysfunction with Novel Therapeutics October 2026 Exhibit 99.1 |
| 01 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
As representatives (the “Representatives”) of the several Underwriters |
| 30 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Exhibit 99.1 Targeting Metabolic Dysfunction with Novel Therapeutics September 2026 |
| 13 Aug 2026 |
8-K: Other Events
On August 13, 2026, Sagimet Biosciences Inc. (the “Company”) announced that the U.S. Food and Drug Administration cleared the Investigational New Drug application and issued a “Study May Proceed” letter for the Company’s Phase 3 clinical... |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. |
| 21 Jul 2026 |
8-K: Regulation FD Disclosure
Exhibit 99.1 Targeting Metabolic Dysfunction with Novel Therapeutics July 2026 |
| 12 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 03 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER the Sagimet Biosciences inc. 2023 STOCK OPTION AND INCENTIVE PLAN |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
Secured equity financing with gross proceeds of $175M in April 2026 |
| 28 Apr 2026 |
8-K: Entry into a Material Definitive Agreement
As representatives (the “Representatives”) of the several Underwriters |
| 27 Apr 2026 |
8-K: Regulation FD Disclosure
Targeting MetabolicDysfunction with Novel Therapeutics April 2026 |
| 27 Apr 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Targeting MetabolicDysfunction with Novel Therapeutics April 2026 Confidential and proprietary information of Sagimet Biosciences Inc. |
| 21 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
On April 20, 2026, Eduardo Martins, M.D., D.Phil. provided notice to Sagimet Biosciences, Inc. (the “Company”) of his retirement from his role as Chief Medical Officer of the Company, effective as of April 20, 2026. Dr. Martins will cont... |
| 11 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Targeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne & Cancer March 2026 |
| 02 Feb 2026 |
8-K: Regulation FD Disclosure
Targeting MetabolicDysfunction with Novel Therapies to Treat MASH, Acne&Cancer February 2026 |
| 18 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
Targeting MetabolicDysfunction with Novel Therapies to Treat MASH, Acne&Cancer December 2025 |
| 17 Dec 2025 |
8-K: Other Events
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected 1H 2026 |
| 23 Oct 2025 |
8-K: Regulation FD Disclosure
Targeting MetabolicDysfunction with Novel Therapies to Treat MASH, Acne&Cancer October 2025 |
Loading...